Q-omics provides the consensus-scored SLC35F5 profile across patient tissues and cancer cell-line models. SLC35F5 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SLC35F5 is differentially expressed in 14, with the highest sampling consensus in KICH. Additionally, SLC35F5 RNA expression shows 21,176 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, KICH, and UVM as cancer lineages where SLC35F5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC35F5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC35F5 survival associations across molecular data types. SLC35F5 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (4) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC35F5 RNA expression–survival associations across cancer types. High SLC35F5 expression shows unfavorable associations in CESC, LGG, ACC, UVM and BLCA, but favorable associations in KIRC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SLC35F5 RNA expression.
This table summarizes SLC35F5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 3. The strongest signals are observed in BLCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for SLC35F5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC35F5 shows lower tumor expression in KICH and THCA and higher tumor expression in BLCA, LUAD, KIRP and HNSC. The KICH box plot shows higher SLC35F5 RNA expression in normal versus tumor tissue (log2 FC = −1.901, t-test p < 0.001).
This table shows molecular features associated with SLC35F5 in patient tissues and cancer cell lines. In patient samples, SLC35F5 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC35F5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LIVER and UPPER_AERODIGESTIVE_TRACT.
